In addition, troglitazone and rosiglitazone, which are PPARγ agonists, also increased the expression of adiponectin receptors; however, they have risks when administered preventively and long term to patients with a previous condition such as metabolic syndrome because hepatotoxicity is a side effect [34,35]. Here, PPARG is linked to metabolic syndrome.